论文部分内容阅读
目的:观察瑞舒伐他汀对老年高胆固醇血症患者血管及血脂内皮舒张功能的影响。方法:41例老年高脂血症患者采用瑞舒伐他汀治疗,另选择41例年龄与性别相匹配的健康老年人作为对照组,检测瑞舒伐他汀治疗前及治疗4周、12周后的血脂水平、肝肾功能和心肌酶谱,采用高频超声测定用药前后的反应性充血和含服硝酸甘油后肱动脉内径的变化。结果:瑞舒伐他汀治疗4、12周后,总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均明显下降(均P<0.01),高密度脂蛋白胆固醇(HDL-C)水平明显上升(P<0.01),其中治疗4周后TC水平下降33.8%,TG水平下降18.8%,LDL-C水平下降40.1%,HDL-C水平上升15.6%,瑞舒伐他汀治疗12周后TC、LDL-C水平明显低于治疗后4周(P<0.01)。瑞舒伐他汀组患者用药前的血管内皮依赖性舒张功能(FMD)明显低于对照组(P<0.01),但用药后FMD值明显增大(P<0.01);而非依赖性血管内皮舒张功能(NMD)用药前后差异无统计学意义(P>0.05)。治疗期间丙氨酸氨基转移酶(ALT)、尿素氮(BUN)、肌酐(Cr)和肌酸磷酸激酶(CK)水平均无明显变化,未见严重不良反应。结论:瑞舒伐他汀对老年高胆固醇血症患者调脂效果显著,且有改善血管内皮依赖性舒张功能的作用。
Objective: To observe the effect of rosuvastatin on the vasodilation and blood lipid endothelium in elderly patients with hypercholesterolemia. Methods: Forty-one elderly patients with hyperlipidemia were treated with rosuvastatin. Another 41 healthy elderly with age and sex were selected as control group. Before and after treatment with rosuvastatin for 4 weeks and 12 weeks Blood lipid, liver and kidney function and myocardial enzymes were measured by high-frequency ultrasound before and after treatment of reactive hyperemia and with nitroglycerin after brachial artery diameter changes. Results: The levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) were significantly decreased in rosuvastatin 4 and 12 weeks after treatment (all P <0.01) After 4 weeks of treatment, TC level decreased by 33.8%, TG level decreased by 18.8%, LDL-C level decreased by 40.1%, HDL-C level increased by 15.6%, and the level of HDL-C increased by 15.6% The levels of TC and LDL-C after treatment with simvastatin for 12 weeks were significantly lower than those for 4 weeks after treatment (P <0.01). The level of endothelium-dependent vasodilatation (FMD) before treatment in rosuvastatin group was significantly lower than that in control group (P <0.01), but FMD was significantly increased after treatment (P <0.01) There was no significant difference in function (NMD) before and after treatment (P> 0.05). ALT, BUN, creatinine and creatine phosphokinase did not change significantly during treatment, and no serious side effects were found. Conclusion: Rosuvastatin has significant lipid-adjusting effect on elderly patients with hypercholesterolemia, and has the effect of improving endothelium-dependent vasodilation.